ESPE2019 Poster Category 2 Growth and Syndromes (to include Turner Syndrome) (28 abstracts)
Hamad General Hospital, Doha, Qatar
The prevalence of biopsy-proven CD in T1D in pediatric populations widely ranges between 2.6 in Finland to 16.4 in Algeria. Many patients with CD and T1D are either asymptomatic (silent CD) or present with only mild symptoms. CD children may be less likely to show overt growth failure but can have weight and height measures at a lower growth percentile and complain of nonspecific symptoms, including anorexia and lassitude.
Aim; Patients and Methods:
This cross-sectional study measured the prevalence of positive serology test and biopsy-proven CD in a large cohort of children T1D (n=365) and compared their growth parameters on the first diagnosis with the growth of children with T1D without CD.
Results:
Celiac Diagnostic criteria | Positive Result | Prevalence |
Total TTG positive | 28/365 | 7.67 % |
ATT IgA | 18/365 | 5% |
ATT IgG | 16/365 | 4.38% |
Both ATT IgA and IgG | 11/365 | 3% |
Biopsy proved | 11/28 (39%) | 3 % |
Groups | T1DM +CD | T1D |
N=17 | N=50 | |
Age (yr) | 7.99 +/−3.5 | 9.1 +/−4.2 |
BMISD (mean +/−SD) | −0.077 +/−1.72 | 0.089 +/−1.39 |
BMISD > 2 SD | 2/17=11.76 % | 6/50=12 % |
BMISD (−1.5 to 1.5 ) | 12/17=70 % | 37/50=75 % |
BMISDS (−1.5−2) | 2/17=11.76 % | 4/50=8 % |
BMISDS <−2 | 2/17=11.76 % | 2/50=4 % |
HSDS (mean +/− SD) | 0.33 +/−1.40 | 0.27 +/−1.29 |
HSDS=or > 2 | 0/17=0 % | 5/50=10 %* |
HSDS (−2 to +2 ) | 14/17=82 % | 44/50=88 % |
HSDS < −2 | 3/17=17.64 %* | 1/50=2% |
The children with obesity who has celiac were short with HSDS <−2 (nutritional dwarfism) while the non-celiac group has a normal height for age.
Conclusion: The prevalence of biopsy-proven CD in our cohort was 3 %. Their BMISDS and HtSDS did not differ compared to controls with T1DM. However, children with T1D + CD had higher % of short stature compared to T1D.